Pancreatic Cancer Research

ResearcherVall d'Hebron Hospital UniversitariActive in the last 2 years

Florian Castet

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5416-5383; OpenAlex author ID A5037592914. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
48
Papers, trials and grants by year

2023: 3 papers · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers

Papers 8

  1. A Phase II Trial to Assess the Evolution of the KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancreatic Ductal Adenocarcinoma Treated With N… Co-author DOI 10.1097/coc.0000000000001253↗
  2. Utility of archived EUS-guided fine-needle biopsy samples for next-generation sequencing in pancreatic adenocarcinoma. Co-author DOI 10.1097/eus.0000000000000197↗
  3. Comparative genomic landscape of acquired resistance in pancreatic cancer treated with pan-RAS or KRASG12C inhibitors Co-author DOI 10.1016/j.annonc.2025.06.018↗
  4. Real-world management and outcome of patients with pancreatic adenocarcinoma. Results of the Spanish RETUD gastrointestinal registry. Co-author DOI 10.1016/j.esmorw.2025.100116↗
  5. HLA-A*02:01allele is associated with decreased risk and a longer survival in pancreatic cancer: Results from an exhaustive analysis of theHLAvariation in PDAC Co-author DOI 10.1101/2024.08.29.24312704↗
  6. Liquid biopsy after resection of pancreatic adenocarcinoma and its relation to oncological outcomes. Systematic review and meta-analysis. Co-author DOI 10.1016/j.ctrv.2023.102604↗
  7. Clinical and genomic characterisation of early-onset pancreatic cancer. Co-author DOI 10.1016/j.ejca.2023.113338↗
  8. Clinical and genomic characterization of pancreatic ductal adenocarcinoma patients with lung oligometastasis. Co-author DOI 10.1016/j.esmogo.2023.08.010↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Teresa Mercade Macarulla · 8 shared papers, 2023–2026 · strength 1.73
  2. Ana P. Vivancos · 4 shared papers, 2023–2026 · strength 0.73
  3. Elizabeth Pando Rau · 2 shared papers, 2023–2026 · strength 0.41
  4. Rafael Álvarez-Gallego · 2 shared papers, 2024–2026 · strength 0.39
  5. Alfredo Carrato Mena · 2 shared papers, 2024–2025 · strength 0.32
  6. Berta Laquente · 1 shared paper, 2026 · strength 0.25
  7. Yolanda Quijano · 1 shared paper, 2026 · strength 0.25
  8. Emilio Vicente · 1 shared paper, 2026 · strength 0.25
  9. Juli Busquets · 1 shared paper, 2026 · strength 0.25
  10. Antonio Cubillo · 1 shared paper, 2026 · strength 0.25
  11. Rodrigo Mata Mata · 1 shared paper, 2026 · strength 0.24
  12. María Teresa Salcedo Allende · 1 shared paper, 2026 · strength 0.24
  13. Piero Alberti · 1 shared paper, 2026 · strength 0.24
  14. Andrés Jesús Muñoz Martín · 1 shared paper, 2025 · strength 0.18
  15. Ismael Ghanem · 1 shared paper, 2025 · strength 0.18
  16. Berta Laquente · 1 shared paper, 2025 · strength 0.18
  17. Ana Fernández Montés · 1 shared paper, 2025 · strength 0.18
  18. Roberto Pazo-Cid · 1 shared paper, 2025 · strength 0.18
  19. Eva Martínez de Castro · 1 shared paper, 2025 · strength 0.18
  20. Enrique Aranda Aguilar · 1 shared paper, 2025 · strength 0.18
  21. Ramón Charco Torra · 1 shared paper, 2023 · strength 0.18
  22. Laura Vidal · 1 shared paper, 2023 · strength 0.18
  23. Josep M. Tabernero · 1 shared paper, 2023 · strength 0.17
  24. Anthony Turpin · 1 shared paper, 2023 · strength 0.15
  25. Natalia Soledad Tissera · 1 shared paper, 2023 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.